Behavioural Pharmacology
February 15, 2021
Michael D. Berquist, William E Fantegrossi
Supplemental Digital Content is available in the text. The objectives of this study were to determine alcohol consumption after administration of (R)(-)-2,5-dimethoxy-4-iodoamphetamine (DOI) or naltrexone in Long–Evans rats, and to assess the effectiveness of these treatments based on individual differences in alcohol consumption. Adult male Long–Evans rats (N = 16) were given opportunities to...
Drug and Alcohol Dependence
January 13, 2020
Michael D. Berquist, Sebastian Leth-Petersen, Jesper L. Kristensen et al.
BACKGROUND Recent clinical studies support the use of 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct treatment for posttraumatic stress disorder (PTSD). Despite these promising findings, MDMA administration in controlled settings can increase blood pressure, heart rate, and body temperature. Previous studies indicate thatO-demethylated metabolites of MDMA contribute to its adverse...
Psychopharmacology
November 15, 2019
Michael D. Berquist, Sebastian Leth-Petersen, Jesper L. Kristensen et al.
There is a renewed interest in the use of 3,4-methylenedioxymethamphetamine (MDMA) for treating psychiatric conditions. Although MDMA has entered phase II clinical trials and shows promise as an adjunct treatment, there is an extensive literature detailing the potential neurotoxicity and adverse neurobehavioral effects associated with MDMA use. Previous research indicates that the adverse...
Behavioural Pharmacology
October 1, 2019
Trent A. Bullock, Michael D. Berquist, Lisa E Baker
Recreational abuse of illicit synthetic cathinones is an ongoing public health concern. Recent studies indicate that the methcathinone derivative 4-methylmethcathinone (4-MMC) produces behavioral and neurochemical effects similar to the entactogen 3,4-methylenedioxymethamphetamine (MDMA). Whereas polysubstance abuse is common, most preclinical studies of drug abuse liability only evaluate the...
Psychopharmacology
November 2017
Michael D. Berquist, Nathyn A Thompson, Lisa E Baker
Although the synthetic cathinone 4-methylmethcathinone (4-MMC, mephedrone) has been a subject of intensive research investigation, the pharmacological mechanisms involved in its interoceptive stimulus effects have yet to be fully characterized. The present study employed drug discrimination methods in rats to compare the interoceptive stimulus properties of two different training doses of 4-MMC...
Neuropharmacology
August 19, 2017
Michael D. Berquist, William S Hyatt, Jonathan J. Bauer-Erickson et al.
Methoxetamine (MXE) is a novel drug of abuse that is structurally similar to phencyclidine (PCP). In the present study, rats were trained to discriminate PCP from saline and substitution tests were performed with arylcyclohexylamines PCP, eticyclidine (PCE), tenocyclidine (TCP), and MXE. PCP and PCE engendered PCP-lever selection in all subjects, whereas MXE and TCP produced PCP-lever selection...
Behavioural Pharmacology
August 2017
Michael D. Berquist, Lisa E Baker
Recreational use of 3,4-methylenedioxypyrovalerone (MDPV) in the early 2000s prompted numerous scientific investigations of its behavioral and neurochemical effects. The purpose of this study was to further characterize the interoceptive stimulus effects of MDPV using a validated in-vivo drug-detection assay. Male Sprague-Dawley rats were trained to discriminate 0.3 mg/kg MDPV from saline under...